Investing Transparency

?? 1606 Corp - CBDW NEWS | 1606 Corp. Signs LOI to Be Acquired by Private Group Seeking to Enter the Public Markets and Utilize AI Technologies for Potential Up listing?? "Focused on acquiring waste management companies, to acquire a controlling position in the Company for $1 million." https://lnkd.in/eEQEmHAJ #Acquisition #AI #wastemanagement #NASDAQ #OTCmarkets #CBDW #equity #innovation #management #CEO #Markets

AI-Powered Communications: Enhancing Investor Engagement A company’s ability to communicate effectively with investors and stakeholders is critical for long-term success. Traditional methods, such as email inquiries and phone support, are becoming inefficient, especially in an era where real-time responses are expected. #AI #Automation #IR #Invesorrelations #Investors #ArtificialIntelligence #1606Corp #CBDW #IR #Publicrelations #Communications #Shareholders

INS Digital recently initiated coverage on CBDW, and here's a brief breakdown of that security. 1606 Corp. (#CBDW) has experienced significant volatility over the past year, with a 52-week range between $0.0040 and $0.1000. The stock’s average daily trading volume is around 1.24 million shares, with approximately 104.25 million shares outstanding and a public float of 98.46 million shares (94.4% of total #shares). While the recent price increase suggests positive momentum, the stock remains highly speculative due to its micro-cap nature and fluctuating #liquidity. Whether CBDW continues to rise depends on sustained investor interest, fundamental business #growth, and broader market conditions. Given the high float and past volatility, price swings are likely, and long-term growth will depend on the company’s ability to execute its #AIdriven strategies effectively.

Exciting Market News! ???? INS Initiates coverage on 1606 Corp. (OTC: CBDW). The stock has been making waves in the market recently but it's the beginning of a rebuild IMO. On March 5, 2025, the stock saw a remarkable surge of 22.89%, climbing from $0.0083 to $0.0102. Just days before, on February 27, 2025, the stock was valued at $0.0076. This upward trajectory mirrors the escalating investor enthusiasm surrounding 1606 Corp.'s cutting-edge AI-driven solutions. The company's strategic collaboration with GPOPlus+ to transform AI-powered distribution solutions for gas stations and convenience stores further underscores its commitment to innovation. Stay tuned for more updates on this dynamic market trend! #MarketUpdate #1606Corp #CBDW #AIInnovation #InvestorNews #Investing #OTCmarkets #Stocks #Equitymarkets #capitalmarkets #CapitalMarkets #stocks

Amplitech Group, Inc. (NASDAQ: AMPG) revolutionizing #5G https://lnkd.in/ebmuH23K

NEWTON GOLF Company (Nasdaq: SPGC) shared preliminary 4Q24 and full-year 2024 financial results, announcing a nearly tenfold increase in annual revenue and higher gross margins—indications of strong acceptance for its next-gen golf shafts, putters, and accessories. Newton Golf is a B2i Digital Featured Company. View their Comprehensive B2i Digital Featured Company Profile at?https://lnkd.in/eCG_9VA6. In the Company’s latest release, preliminary results pointed to: ·????4Q24 Revenue: Projected at $1.1M–$1.3M, up roughly 882% over 4Q23 ·????4Q24 Gross Margin: Expected at 72–74%, compared to 36% in 4Q23 ·????Full-Year 2024 Revenue: Projected at $3.4M–$3.6M, nearly 10x 2023 levels ·????Key 2024 Milestones: Complete rebranding, expanded retail footprint in Japan, introduction of new premium shafts, plus strong e-commerce performance In a statement, Executive Chairman Greg Campbell said, “Our expected improved results in 4Q24 and full year 2024 is reflective of the growing acceptance of our unique technology and design elements in our putters and replacement shafts. We recognized significantly increased sales of our NEWTON Motion replacement shafts throughout 2024 from both professional and recreational golfers, and we expect that momentum to continue in 2025. Despite it being generally off season for golf, we were pleased with our Black Friday and Cyber Monday sales, and we look forward to improved gross margin performance as we scale production and bring down unit cost.” Read the full press release:?https://lnkd.in/eAfFDd4R As a subsidiary of Sacks Parente Golf, Inc., NEWTON GOLF is a technology-forward golf brand recognized for its groundbreaking advancements, including Vernier Acuity putters, ULBP technology, and ultra-light carbon fiber shafts. The Company is committed to producing high-quality golf equipment in the U.S. while expanding into new product lines and international markets. Led by Executive Chairman?Greg Campbell, Newton Golf’s leadership team brings deep industry expertise, including Chief Technology Officer?Akinobu Yorihiro. For questions about Newton Golf, please contact Investor Relations at?[email protected]. #NEWTONGolf #GolfInnovation #FinancialResults #B2iDigital #GolfEquipment

The B2i Digital team is pleased to share an important news announcement from our Featured Company,?OS Therapies, Inc. (NYSE-A: OSTX). The company announced at the?J.P. Morgan Healthcare Conference?that its Phase 2b Clinical Trial of OST-HER2 (OST31-164) achieved the primary endpoint of 12-month Event Free Survival (EFS) with statistical significance (33% vs. 20% in historical controls; p=0.0158). This milestone underscores OST-HER2's potential in preventing the recurrence of fully resected, lung metastatic osteosarcoma, an indication with no currently approved treatments. Chair and CEO Paul Romness?commented on the importance of the results: “The achievement of the primary endpoint in the OST-HER2 phase 2b is a tremendous success that opens the possibility, for the first time, of meaningful therapy for patients suffering from osteosarcoma with lung metastases after resection. This is a leap forward in the development of OST-HER2 and we are pleased that our regulatory strategy is consistent with the FDA’s recent draft guidance update for accelerated approvals. With these positive data in hand, we are preparing to engage with U.S. FDA on an accelerated pathway for approval in this extremely challenging indication. We do not expect to have to treat additional patients as part of this process with FDA.” Robert Petit (Chief Medical and Scientific Officer)?further commented, “We are extremely pleased with these results of our Phase 2b clinical trial because they show that OST-HER2-treated patients achieved the primary endpoint of 12-month EFS in a statistically significantly higher ratio than comparable historical controls, in addition to increasing the likelihood of 1-year and 2-year survival as compared with comparable historical controls. The strong safety profile shown in this study also supports the use of OST-HER2 in this incredibly difficult-to-treat population that has no currently approved therapies.” View the full release at:?https://lnkd.in/eYPVvpBy Led by?CEO Paul Romness?and a highly experienced executive team, including?Chris Acevedo (CFO),?Robert Petit (Chief Medical and Scientific Officer),?John Doll (Chief of Staff), and?Gerald Commissiong (Chief Business Officer), OS Therapies is committed to developing innovative immunotherapies and advanced drug technologies to address hard-to-treat cancers. The company is advancing its “tunable ADC” technology platform, which aims to transform cancer care by precisely targeting tumors with customizable therapies. Learn more about OS Therapies’ work at?https://lnkd.in/epFNRZQB For investor-related questions, please visit?OS Therapies' Investor Relations page?or email?[email protected]. #OSTherapies #Immunotherapy #Oncology #Biotechnology #B2iDigital

We want to welcome Soligenix, Inc. to the DealFlow Events Microcap Conference January 28th – 30th, 2025, held at the Borgata Hotel Casino & Spa in Atlantic City, NJ. See their profile on B2i Digital at https://lnkd.in/efvrJC7Z Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. We have two areas of focus: 1) a specialized biotherapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, psoriasis, oral mucositis, Beh?et’s disease, and pediatric Crohn’s disease. 2) a public health solutions segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure and viral disease including Ebola, Marburg and COVID-19. We look forward to seeing the continued results from Christopher J. Schaber, PhD, Oreola Donini, Jonathan Guarino, CPA, Adam Rumage, Richard Straube and the entire Soligenix, Inc. team! Thanks to the exceptional team at DealFlow Events for organizing this conference: Phillip LoFaso, Brooke Grieff, Morgan Cropsey, Steve Dresner, Julius Picardi and many others This premier event is the largest independent microcap investing conference in the U.S., offering a unique platform for company executives, institutional investors, retail investors, and capital markets professionals to connect through presentations, one-on-one meetings, and expert-led panels. #MicrocapConference #DealFlowEvents #B2iDigital #InvestorConference #GrowthCompanies